Gainers

• Indaptus Therapeutics (NASDAQ:INDP) stock increased by 18.6% to $2.55 during Monday's after-market session. The company's market cap stands at $4.7 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 12.19% to $2.3. The market value of their outstanding shares is at $1.9 million.
• Biodesix (NASDAQ:BDSX) shares increased by 10.2% to $12.42. The market value of their outstanding shares is at $88.6 million. As per the news, the Q1 earnings report came out today.
• HealthStream (NASDAQ:HSTM) shares rose 9.45% to $23.26. The market value of their outstanding shares is at $607.2 million. As per the news, the Q1 earnings report came out today.
• Greenland Mines (NASDAQ:GRML) shares increased by 6.25% to $0.51. The market value of their outstanding shares is at $62.5 million.
• Skye Bioscience (NASDAQ:SKYE) stock moved upwards by 5.74% to $0.92. The company's market cap stands at $28.9 million.

Losers

• GeneDx Holdings (NASDAQ:WGS) stock fell 44.8% to $37.49 during Monday's after-market session. The market value of their outstanding shares is at $1.9 billion. The company's, Q1 earnings came out today.
• Sangamo Therapeutics (NASDAQ:SGMO) shares fell 14.7% to $0.15. The company's market cap stands at $50.1 million.
• Inspire Medical Systems (NYSE:INSP) shares declined by 14.26% to $47.02. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q1 earnings came out today.
• Ocugen (NASDAQ:OCGN) shares declined by 9.19% to $1.68. The market value of their outstanding shares is at $609.3 million.
• Lunai Bioworks (NASDAQ:LNAI) shares declined by 8.51% to $0.3. The market value of their outstanding shares is at $11.6 million.
• Can Fite Biopharma (AMEX:CANF) stock fell 6.63% to $3.1. The company's market cap stands at $6.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.